{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:36:00Z","timestamp":1790649360930,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research (NIHR)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bprclinrheum.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.berh.2014.10.004","type":"journal-article","created":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T08:00:54Z","timestamp":1415347254000},"page":"711-728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis"],"prefix":"10.1016","volume":"28","author":[{"given":"Pedro M.","family":"Machado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siba P.","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2014.10.004_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.berh.2014.10.004_bib2","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib3","first-page":"758","article-title":"A\u00a0methodologic framework for developing and selecting endpoints in clinical trials","volume":"9","author":"Tugwell","year":"1982","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ard.51.2.177","article-title":"Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis","volume":"51","author":"van der Heijde","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib5","first-page":"198","article-title":"The OMERACT filter for outcome measures in rheumatology","volume":"25","author":"Boers","year":"1998","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib6","first-page":"951","article-title":"Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in ankylosing spondylitis","volume":"26","author":"van der Heijde","year":"1999","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/BOR.0b013e3283470f23","article-title":"How to measure disease activity in axial spondyloarthritis?","volume":"23","author":"Machado","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib8","first-page":"2286","article-title":"A\u00a0new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/rheumatology\/keh595","article-title":"Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives","volume":"44","author":"Spoorenberg","year":"2005","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.berh.2014.10.004_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/art.20233","article-title":"The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the bath ankylosing spondylitis disease activity index","volume":"51","author":"Heuft-Dorenbosch","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.004_bib11","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1136\/ard.2008.099226","article-title":"Comparison of the bath ankylosing spondylitis disease activity index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations","volume":"68","author":"Song","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/rheumatology\/35.1.66","article-title":"The bath ankylosing spondylitis patient global score (BAS-G)","volume":"35","author":"Jones","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib14","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/rheumatology\/kes142","article-title":"Sensitivity and discriminatory ability of the ankylosing spondylitis disease activity score in patients treated with etanercept or sulphasalazine in the ASCEND trial","volume":"51","author":"van der Heijde","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.berh.2014.10.004_bib16","article-title":"Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis","author":"Kilic","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s10067-014-2729-5","article-title":"Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS?","volume":"33","author":"Au","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib18","first-page":"78","article-title":"Ankylosing spondylitis functional and activity indices in clinical practice","volume":"7","author":"Popescu","year":"2014","journal-title":"J\u00a0Med Life"},{"key":"10.1016\/j.berh.2014.10.004_bib19","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/annrheumdis-2012-202976","article-title":"Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme","volume":"73","author":"Fernandez-Espartero","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jbspin.2013.01.003","article-title":"Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients","volume":"80","author":"Godfrin-Valnet","year":"2013","journal-title":"Joint Bone Spine: Rev Du Rhum"},{"key":"10.1016\/j.berh.2014.10.004_bib21","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/rheumatology\/kes057","article-title":"Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria","volume":"51","author":"Fagerli","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.berh.2014.10.004_bib22","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ard.2009.111187","article-title":"Responsiveness of the ankylosing spondylitis disease activity score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors","volume":"69","author":"Pedersen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib23","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/rheumatology\/ker087","article-title":"The ankylosing spondylitis disease activity score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-alpha inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China","volume":"50","author":"Xu","year":"2011","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.berh.2014.10.004_bib24","first-page":"752","article-title":"Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis","volume":"28","author":"Aydin","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1756-185X.2010.01537.x","article-title":"Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis","volume":"13","author":"Nas","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib26","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1136\/ard.2010.129726","article-title":"Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?","volume":"69","author":"Eder","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib27","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00296-014-2955-9","article-title":"Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity","volume":"34","author":"Salaffi","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2014.10.004_bib28","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/annrheumdis-2012-202245","article-title":"Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis","volume":"72","author":"Paramarta","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib30","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.004_bib31","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2003.016717","article-title":"Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis","volume":"63","author":"Brandt","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib32","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3899\/jrheum.111481","article-title":"Patient-acceptable symptom state as an outcome measure in the daily care of patients with ankylosing spondylitis","volume":"39","author":"Rodriguez-Lozano","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib33","first-page":"106","article-title":"Evaluation and stability of the patient acceptable symptom state (PASS) over time in patients with ankylosing spondylitis","volume":"30","author":"Wariaghli","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2011-200308","article-title":"Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study","volume":"71","author":"Braun","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib35","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib36","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/ar4244","article-title":"Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years","volume":"15","author":"Baraliakos","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.004_bib37","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38140","article-title":"Tumor necrosis factor alpha inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort","volume":"65","author":"Ciurea","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.004_bib38","first-page":"204","article-title":"ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy","volume":"10","author":"Vastesaeger","year":"2014","journal-title":"Rheumatol Clin"},{"issue":"10","key":"10.1016\/j.berh.2014.10.004_bib39","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3899\/jrheum.140056","article-title":"Consistently good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial","volume":"41","author":"Song","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib40","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3899\/jrheum.131003","article-title":"The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial","volume":"41","author":"van der Heijde","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib41","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib42","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3899\/jrheum.110279","article-title":"Endorsement of definitions of disease activity states and improvement scores for the ankylosing spondylitis disease activity Score: results from OMERACT 10","volume":"38","author":"Machado","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib43","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/ard.2010.138883","article-title":"ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFalpha inhibitors","volume":"70","author":"Pedersen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib44","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/annrheumdis-2012-201999","article-title":"MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a TNF inhibitor","volume":"71","author":"Machado","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib45","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.004_bib46","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrrheum.2013.93","article-title":"Spondyloarthritis: Is it time to replace BASDAI with ASDAS?","volume":"9","author":"Machado","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib47","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib48","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib49","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2014.10.004_bib51","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2014.10.004_bib52","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3899\/jrheum.120822","article-title":"GRAPPA responder index project (GRACE): a report from the GRAPPA 2011 annual meeting","volume":"39","author":"Helliwell","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2014.10.004_bib53","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/acr.20577","article-title":"Measures of psoriatic arthritis","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.berh.2014.10.004_bib54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/247553031016a00202","article-title":"The self-administered psoriasis and arthritis screening questionnaire (PASQ): a sensitive and specific tool for the diagnosis of early and established psoriatic arthritis","volume":"16","author":"Khraishi","year":"2010","journal-title":"Psoriasis Forum"},{"issue":"4","key":"10.1016\/j.berh.2014.10.004_bib55","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2007.04.001","article-title":"The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool","volume":"57","author":"Husni","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.berh.2014.10.004_bib56","first-page":"469","article-title":"Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the psoriasis epidemiology screening tool (PEST) questionnaire","volume":"27","author":"Ibrahim","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2014.10.004_bib57","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3899\/jrheum.101117","article-title":"Toronto psoriatic arthritis screening (ToPAS) questionnaire: a report from the GRAPPA 2009 annual meeting","volume":"38","author":"Chandran","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib58","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/ard.2006.051706","article-title":"Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors","volume":"65","author":"Fransen","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib59","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.004_bib60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"Van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.004_bib61","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/art.37939","article-title":"Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease","volume":"65","author":"Coates","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.004_bib62","first-page":"1167","article-title":"Consensus on a core set of domains for psoriatic arthritis","volume":"34","author":"Gladman","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2014.10.004_bib63","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2133.1991.tb04952.x","article-title":"Measurement of involved surface area in patients with psoriasis","volume":"124","author":"Ramsay","year":"1991","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2014.10.004_bib64","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"4","key":"10.1016\/j.berh.2014.10.004_bib65","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment","volume":"51","author":"Langley","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2014.10.004_bib66","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/1523-1747.ep12329912","article-title":"The self-administered psoriasis area and severity index is valid and reliable","volume":"106","author":"Feldman","year":"1996","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2014.10.004_bib67","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1365-2133.2000.03418.x","article-title":"The salford psoriasis index: an holistic measure of psoriasis severity","volume":"142","author":"Kirby","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2014.10.004_bib68","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","article-title":"Physician global assessment (PGA) and psoriasis area and severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis","volume":"66","author":"Robinson","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2014.10.004_bib69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1468-3083.2009.03562.x","article-title":"What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature","volume":"24","author":"Puzenat","year":"2010","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.berh.2014.10.004_bib70","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1185\/030079908X291985","article-title":"Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis","volume":"24","author":"Reich","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.berh.2014.10.004_bib71","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2133.2006.07389.x","article-title":"A\u00a0study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: psoriasis area and severity index, physician's global assessment and lattice system physician's global assessment","volume":"155","author":"Berth-Jones","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2014.10.004_bib72","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3899\/jrheum.130456","article-title":"Psoriasis outcome measures: a report of the GRAPPA 2012 annual meeting","volume":"40","author":"Gottlieb","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2014.10.004_bib73","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jaad.2003.09.014","article-title":"A\u00a050% reduction in the psoriasis area and severity index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis","volume":"50","author":"Carlin","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2014.10.004_bib74","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2230.1991.tb01232.x","article-title":"The finger-tip unit: a new practical measure","volume":"16","author":"Long","year":"1991","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.berh.2014.10.004_bib75","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/art.24562","article-title":"International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis","volume":"61","author":"Chandran","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.004_bib76","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2014.10.004_bib77","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2230.2006.02305.x","article-title":"Interobserver reliability of the nail psoriasis severity Index","volume":"32","author":"Aktan","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.berh.2014.10.004_bib78","first-page":"123","article-title":"The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2014.10.004_bib79","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.130163","article-title":"Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era","volume":"40","author":"Gladman","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib80","first-page":"1745","article-title":"Development of an assessment tool for dactylitis in patients with psoriatic arthritis","volume":"32","author":"Helliwell","year":"2005","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2014.10.004_bib81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/keq262","article-title":"Observational cohort studies: lessons learnt from the University of Toronto psoriatic arthritis program","volume":"50","author":"Gladman","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2014.10.004_bib82","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/art.22758","article-title":"The concept of a \u201csynovio-entheseal complex\u201d and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond","volume":"56","author":"McGonagle","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2014.10.004_bib83","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/ard.46.3.197","article-title":"Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis","volume":"46","author":"Mander","year":"1987","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2014.10.004_bib84","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"9313","key":"10.1016\/j.berh.2014.10.004_bib85","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.berh.2014.10.004_bib86","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/ard.2007.084244","article-title":"Development and validation of the spondyloarthritis research consortium of Canada (SPARCC) enthesitis index","volume":"68","author":"Maksymowych","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2014.10.004_bib87","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Care Res"},{"issue":"238","key":"10.1016\/j.berh.2014.10.004_bib88","first-page":"127","article-title":"Psoriatic arthritis (PSA)\u2014an analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Q\u00a0J Med"},{"issue":"4","key":"10.1016\/j.berh.2014.10.004_bib89","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","article-title":"Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients","volume":"30","author":"Alonso","year":"1991","journal-title":"Br J Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2014.10.004_bib90","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/rheumatology\/33.2.133","article-title":"Classification of clinical subsets in psoriatic arthritis","volume":"33","author":"Veale D","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib91","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.24280","article-title":"Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis","volume":"61","author":"Fernandez-Sueiro","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2014.10.004_bib92","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.20421","article-title":"Could the bath ankylosing spondylitis disease activity index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis?","volume":"51","author":"Taylor","year":"2004","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2014.10.004_bib93","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2014.10.004_bib94","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.3899\/jrheum.091172","article-title":"Informing response criteria for psoriatic arthritis. I: discrimination models based on data from3 anti-tumor necrosis factor randomized studies","volume":"37","author":"Gladman","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2014.10.004_bib95","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.3899\/jrheum.100479","article-title":"Informing response criteria for psoriatic arthritis (PsA). II: further considerations and a proposal\u2014the PsA joint activity index","volume":"37","author":"Gladman","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib96","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ard.2010.129379","article-title":"Development of a preliminary composite disease activity index in psoriatic arthritis","volume":"70","author":"Mumtaz","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2014.10.004_bib97","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/annrheumdis-2011-200093","article-title":"Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set","volume":"71","author":"FitzGerald","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib98","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib99","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.004_bib100","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3899\/jrheum.101116","article-title":"Composite measures in psoriatic arthritis: a report from the GRAPPA 2009 annual meeting","volume":"38","author":"Helliwell","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.004_bib101","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694214000862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694214000862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:51:46Z","timestamp":1747151506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694214000862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1521694214000862"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2014.10.004","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2014.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}